GlassScriptPhysician profile
William Joseph Scheuing
NPI 1477117422
$1,756.13
in general payments reported to CMS, 2019-2025
11 companies · $436 in 2025
The $436 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.83 · 2023: $589 · 2024: $714 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,738.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $429.53 | 2020-2024 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $394.29 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $341.05 | 2023-2024 | Saphnelo |
| Janssen Biotech, INC. | $188.39 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $106.73 | 2023 | Taltz |
| Glaxosmithkline, LLC. | $97.44 | 2024-2025 | Nucala, Benlysta |
| Pfizer INC. | $58.16 | 2024-2025 | |
| Ucb, INC. | $51.27 | 2025 | Bimzelx |
| Alexion Pharmaceuticals, INC. | $43.35 | 2023-2024 | Strensiq |
| Amgen INC. | $32.10 | 2025 | Tavneos, Enbrel, Otezla |
| E.R. Squibb & Sons, L.L.C. | $13.82 | 2025 | Orencia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Scheuing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.